Safety outcomes in patients with rheumatoid arthritis treated with abatacept: results from a multinational surveillance study across seven European registries

Arthritis Research & Therapy

Research

Carlos Sánchez-Piedra¹  Fernando Sánchez-Alonso¹  Alyssa Dominique²  T. Christopher Bond²  Teresa A. Simon²  Tzuyung Douglas Kou²  Merete Lund Hetland³  Florenzo Iannone⁴  Roberto Caporali⁵  Dan Nordstrom⁶  Axel Finckh⁷  Karel Pavelka⁸  Maria Victoria Hernandez⁹  Jacques-Eric Gottenberg^1,10 

[1] BIOBADASER, Research Unit, Sociedad Española de Reumatología, Madrid, Spain;Bristol Myers Squibb, 08534, Princeton, NJ, USA;DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopedics, Rigshospitalet, Glostrup, Denmark;Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark;DETO-Rheumatology Unit, University of Bari, Bari, Italy;Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy;ASST PINI-CTO Hospital, Milan, Italy;Departments of Medicine and Rheumatology, Helsinki University Hospital and Helsinki University, Helsinki, Finland;Division of Rheumatology, University Hospitals of Geneva, Geneva, Switzerland;Institute of Rheumatology, Prague, Czech Republic;Rheumatology Department, Hospital Clinic of Barcelona, Barcelona, Spain;Strasbourg University Hospitals, Strasbourg, France;

关键词: Rheumatoid arthritis;    Abatacept;    Biologic DMARD;    Safety;    Infections;    Malignancy;   

DOI  :  10.1186/s13075-023-03067-x

 received in 2022-12-05, accepted in 2023-05-11,  发布年份 2023

来源: Springer

【 摘 要 】

BackgroundPatients with rheumatoid arthritis (RA) have an increased risk of infection and malignancy compared with the general population. Infection risk is increased further with the use of disease-modifying antirheumatic drugs (DMARDs), whereas evidence on whether the use of biologic DMARDs increases cancer risk remains equivocal. This single-arm, post-marketing study estimated the incidence of prespecified infection and malignancy outcomes in patients with RA treated with intravenous or subcutaneous abatacept.MethodsData were included from seven European RA quality registries: ATTRA (Anti-TNF Therapy in Rheumatoid Arthritis [Czech Republic]), DANBIO (Danish Rheumatologic Database), ROB-FIN (National Registry of Antirheumatic and Biological Treatment in Finland), ORA (Orencia and Rheumatoid Arthritis [France]), GISEA (Italian Group for the Study of Early Arthritis), BIOBADASER (Spanish Register of Adverse Events of Biological Therapies in Rheumatic Diseases), and the SCQM (Swiss Clinical Quality Management) system. Each registry is unique with respect to design, data collection, definition of the study cohort, reporting, and validation of outcomes. In general, registries defined the index date as the first day of abatacept treatment and reported data for infections requiring hospitalization and overall malignancies; data for other infection and malignancy outcomes were not available for every cohort. Abatacept exposure was measured in patient-years (p-y). Incidence rates (IRs) were calculated as the number of events per 1000 p-y of follow-up with 95% confidence intervals.ResultsOver 5000 patients with RA treated with abatacept were included. Most patients (78–85%) were female, and the mean age range was 52–58 years. Baseline characteristics were largely consistent across registries. Among patients treated with abatacept, IRs for infections requiring hospitalization across the registries ranged from 4 to 100 events per 1000 p-y, while IRs for overall malignancy ranged from 3 to 19 per 1000 p-y.ConclusionsDespite heterogeneity between registries in terms of design, data collection, and ascertainment of safety outcomes, as well as the possibility of under-reporting of adverse events in observational studies, the safety profile of abatacept reported here was largely consistent with previous findings in patients with RA treated with abatacept, with no new or increased risks of infection or malignancy.

【 授权许可】

CC BY   
© The Author(s) 2023

【 图 表 】

Fig. 1

41116_2023_37_Article_IEq153.gif